INTRODUCTION
============

Acute kidney injury (AKI) is a frequent complication in critically ill patients, associated with increased morbidity and mortality.^(^ [@B1] ^)^ Renal replacement therapy (RRT) is sometimes needed to control azotemia, fluid balance and electrolyte and acid-base imbalances; it is a cornerstone of treatment in more severe cases.^(^ [@B2] ^)^ Although controversial, continuous RRT (CRRT) has become a routine therapy for AKI in many countries, given the lower hemodynamic compromise and higher renal recovery rates compared to intermittent hemodialysis.^(^ [@B2] ^)^

The impact of different therapeutic interventions on the microcirculation of critically ill patients has been reported.^(^ [@B3] ^)^ Microcirculatory dysfunction has also been associated with worse outcomes in septic shock patients^(^ [@B4] ^)^ and others.^(^ [@B3] ^)^ Microcirculatory dysfunction may translate into worse outcomes in patients submitted to RRT. In these patients, CRRT may be used to mitigate dysfunction due to higher hemodynamic stability and maintenance of sufficient perfusion pressure in the course of therapy.

Microcirculatory changes are known to play a role in pathophysiology of AKI. Still, only one study assessing microcirculatory changes associated with RRT in patients with AKI has been published to date.^(^ [@B5] ^)^

OBJECTIVE
=========

To address the impacts of continuous venovenous hemodiafiltration on the microcirculation of patients with acute kidney injury.

METHODS
=======

This study was conducted in compliance with STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) guidelines.^(^ [@B6] ^)^

Study design and setting
------------------------

A prospective, observational pilot study conducted in a 40-bed, open clinical-surgical high-density intensive care unit (ICU) of a private tertiary care hospital located in the city of São Paulo (SP), Brazil. This study was approved by the Ethics Committee of *Hospital Israelita Albert Einstein*, protocol 1.467.160, CAAE: 54067916.4.0000.0071. Written Informed Consent was obtained from all participants or their next of kin.

Inclusion and exclusion criteria
--------------------------------

The following patients were consecutively included: (1) age ≥18 years; (2) affected with AKI (according to KDIGO criteria)^(^ [@B7] ^)^ and undergoing continuous venovenous hemodiafiltration (CVVHDF). Exclusion criteria were as follows: diagnosis of chronic kidney disease; pregnancy and high risk of death within the next 24 hours.

Continuous venovenous hemodiafiltration protocol
------------------------------------------------

Patients received CVVHDF according to pre-established local guidelines.^(^ [@B8] ^)^ In all cases, CVVHDF was indicated and conducted by expert nephrologists. Following CVVHDF indication, a triple lumen catheter (Arrow International, PA, USA) was inserted into the internal jugular or femoral vein.^(^ [@B8] ^)^ Continuous venovenous hemodiafiltration was performed using a Prisma machine (Gambro Renal Products, France).

The Prisma machine was primed with 1,000mL of normal saline solution.^(^ [@B8] ^)^ Blood samples were collected as dictated by the institutional protocol for determination of the optimal dialysis solution composition.^(^ [@B8] ^)^ Ionized calcium was measured every 6 hours. Sodium and potassium levels, and arterial blood gases were analyzed every 12 hours. Creatinine, urea, magnesium, total calcium, chloride and phosphorus levels were measured once daily.^(^ [@B8] ^)^

Standard dialysis solution consisted of sodium (110mEq/L), chloride (111mEq/L), magnesium (1.5mEq/L) and dextrose 0.1%.^(^ [@B8] ^)^ Sodium bicarbonate, potassium phosphate and magnesium sulfate were added as needed. Solution temperature was approximately 35°C.^(^ [@B8] ^)^

Near-infrared spectroscopy monitoring
-------------------------------------

Following the indication of CVVHDF by the nephrologist, microcirculation was assessed using near-infrared spectroscopy (NIRS) (InSpectra Tissue Spectrometer model 650; Hutchinson Technology Inc., Hutchinson, MN, USA) by means of a 15mm probe placed over the thenar eminence.^(^ [@B9] ^)^ After a 3-minute period of minimal tissue oxygen saturation (SatO~2~) variation and NIRS signal stabilization, basal SatO~2~ was recorded and a vascular occlusion test (VOT) performed by inflating a sphygmomanometer cuff to 30mmHg higher than the systolic arterial pressure, as described elsewhere.^(^ [@B9] ^)^ The cuff was kept inflated for 3 minutes, then quickly deflated.^(^ [@B9] ^)^ SatO~2~ was continuously recorded for 5 minutes during the reperfusion phase. Near-infrared spectroscopy derived parameters were monitored immediately before CVVHDF initiation, then after 1, 4 and 24 hours.

Near-infrared spectroscopy derived parameters were calculated using a research software (Hutchinson Technology Inc., Hutchinson, MN, USA). SatO~2~ (%) and tissue hemoglobin index (THI) were measured at baseline. The descending slope (%/minute) was calculated from baseline to minimum SatO~2~ (SatO~2~min) immediately after the end of the VOT. The ascending slope (%/minute) was calculated from SatO~2~min to maximum SatO~2~ (SatO~2~max) immediately after the end of the VOT. The area under the curve of reactive hyperemia was calculated from SatO~2~max to return to baseline SatO~2~.

Data collection and outcomes
----------------------------

Age, sex, body mass index (BMI), reason for ICU admission, comorbidities and the Simplified Acute Physiology Score (SAPS III) were recorded upon ICU admission. Systemic hemodynamic variables, ventilatory parameters, use of vasopressors and sedatives, capillary refill time, forearm-to-fingertip skin temperature gradient^(^ [@B9] ^)^ and the peripheral perfusion index (Radical-7 Pulse CO-Oximeter; Masimo Corporation, Irvine, CA, USA) were recorded at the time of NIRS measurement. Arterial blood gases were recorded as close as possible to NIRS measurement. The Sequential Organ Failure Assessment (SOFA) score was recorded during the first 24 hours following ICU admission. Outcomes of interest were length of in-hospital and ICU stay, ICU mortality, in-hospital mortality and 28-day mortality.

Endpoints
---------

The primary endpoint was the assessment of NIRS-derived parameters immediately before, then 1, 4, and 24 hours after CVVHDF initiation. The following parameters were assessed: baseline, minimum and maximum SatO~2~, descending and ascending slope, THI, recovery time and hyperemic area.^(^ [@B9] ^)^

Statistical analysis
--------------------

Data were reported as median (interquartile range) and absolute numbers (percentage). Parameters measured at the four experimental time points were analyzed using the univariate or the multivariate (adjusted for SOFA and SAPS III) linear mixed model, with patients introduced as random effect. The level of significance was set at p\<0.05. Statistical analyses were performed using R 3.4.1 (R Foundation for Statistical Computing, Vienna, Austria).

RESULTS
=======

Baseline characteristics
------------------------

Nine patients were included over a period of 2 months. Most patients were men (77.8%), presented with sepsis-induced AKI (66.7%), and were admitted to ICU due to non-surgical reasons. Urinary output immediately before and 24 hours after the initiation of RRT was zero in all cases; 44.6% of patients required mechanical ventilation, and 33.3% received norepinephrine ([Tables 1](#t1){ref-type="table"} and [2](#t2){ref-type="table"}).

Table 1Patient characteristicsCharacteristics(n=9)Age, years66 (61-76)Male gender7/9 (77.8)BMI, kg/m^2^26.20 (22.77-27.17)Time from hospital admission to inclusion, days3 (2-16)Time from ICU admission to inclusion, days2 (1-3)Etiology of acute kidney injury Sepsis6/9 (66.7)Pancreatitis1/9 (11.1)Drug1/9 (11.1)Acute exacerbation of chronic renal disease1/9 (11.1)Type of ICU admission Medical9/9 (100.0)Surgical0/9 (0.0)Source of admission Emergency department4/9 (44.4)Step down unit4/9 (44.4)Other hospital1/9 (11.1)Comorbidities Hypertension5/9 (55.5)Active cancer3/9 (33.3)Congestive heart failure2/9 (22.2)Coronary insufficiency1/9 (11.1)*Diabetes mellitus*1/9 (11.1)Diagnosis upon admission Respiratory3/9 (33.3)Cardiovascular1/9 (11.1)Gastrointestinal1/9 (11.1)Metabolic1/9 (11.1)Neurological1/9 (11.1)Renal1/9 (11.1)Sepsis1/9 (11.1)SAPS III60 (51-63)SOFA9 (5-11)Baseline creatinine, mg/dL1.00 (0.80-1.90)Creatinine prior to RRT, mg/dL2.83 (2.41-3.61)Creatinine clearance prior to RRT, mL/minute25.29 (11.94-37.10)Urine output 24 hours prior to RRT, mL/kg/hour0.63 (0.28-0.87)Urea prior RRT, mg/dL74 (58-87)Arterial blood gas and vital signs pH7.37 (7.25-7.42)PaO~2~, mmHg99.40 (93.85-145.50)PaCO~2~, mmHg39.10 (31.50-40.85)Base excess, mEq/L-3.05 (-13.08-2.90)Lactate, mg/dL12.00 (10.94-15.00)Hemoglobin, g/dL8.50 (8.10-11.10)Mechanical ventilation4/9 (44.4)Respiratory rate, bpm16 (15-19)PaO~2~/FiO~2~400 (311-457)Tidal volume, mL/kg PBW6.28 (5.84-9.11)PEEP, cmH~2~O10.0 (9.5-10.5)CVVHDF characteristics Catheter in right internal jugular vein8/9 (88.9)Blood flow, mL/minute100 (100-100)Citrate flow, mL/hour155 (150-160)Dialysate flow, mL/hour2,000 (2,000-2,000)Replacement flow, mL/hour600 (600-600)Ultrafiltration rate, mL/hour190 (150-250)Dose, mL/kg/hour37.10 (33.30-40.86)Length of in-hospital stay (survivors), days29 (23-59)Length of ICU stay (survivors), days12 (7-15)ICU mortality0/9 (0)In-hospital mortality2/9 (22.2)28-day mortality1/9 (11.1)[^2]

Table 2Vital signs and near-infrared spectroscopy-derived parameters during continuous venovenous hemodiafiltration Before CVVHDF1 hour after CVVHDF4 hours after CVVHDF24 hours after CVVHDFUnadjusted p value^\*^Adjusted p value^†^Vital signs      Heart rate, bpm83 (73-113)81 (76-104)82 (69-88)77 (65-85)0.1340.135MAP, mmHg83 (78-96)80 (72-89)83 (74-91)87 (78-93)0.4580.415CVP, mmHg10 (8-11)18 (6-19)9 (8-11)12 (10-12)0.8950.912SpO~2~, %97 (95-99)97 (97-97)97 (96-98)97 (93-98)0.4870.478Capillary refill time, second1.86 (1.56-1.98)2.20 (1.62-2.45)2.57 (1.83-3.07)2.47 (1.81-2.91)0.0700.078Forearm-to-fingertip skin temperature gradient, °C1.80 (- 0.10-3.40)1.60 (0.10-1.90)1.15 (0.35-2.93)2.05 (0.80-2.83)0.9570.989PPI, %1.40 (0.72-2.00)1.40 (0.73-1.60)0.95 (0.53-1.78)0.71 (0.56-1.00)0.1490.156Norepinephrine      Number of patients3 / 9 (33.3)3 / 9 (33.3)3 / 9 (33.3)3 / 9 (33.3)\-\-\-\-\--μg/kg/minute0.11 (0.07-0.52)0.13 (0.07-0.66)0.10 (0.06-0.65)0.21 (0.15-0.37)0.6350.635Urine output 24 hours after RRT, mL/kg/hour\-\-\-\-\-\-\-\--0.08 (0.03-0.64)\-\-\-\-\--Urine output 24 hours after RRT, mL/kg/hour\-\-\-\-\-\-\-\-\-- 89 (- 1,070-1,083)\-\-\-\-\--NIRS-derived parameters      THI11.8 (10.5-12.9)9.0 (7.9-9.8)9.6 (7. 2-11.4)11.1 (7.6-11.9)0.1560.127SatO~2~, %83 (81-89)80 (76-84)81 (73-84)81 (78-83)0.2270.187SatO~2~ min, %64 (49-67)55 (54-60)55 (51-59)52 (43-59)0.0290.023SatO~2~ max, %94 (87-95)88 (83-93)90 (81-93)90 (87-93)0.2370.210Descending slope, %/minute8.3 (4.4-10.4)7.7 (6.0-9.8)7.4 (7.3-8.6)10.5 (10.4-12.5)0.0520.088Ascending slope, %/second1.6 (1.2-3.1)2.2 (1.9-2.6)1.9 (1.2-2.4)2.7 (1.9-3.3)0.6560.607Recovery time, second31.0 (29.5-48.5)34.0 (31.5-69.0)28.5 (27.3-61.3)23.0 (20.8-29.0)0.2640.435SatO~2~max - SatO~2~min, %7.0 (5.5-9.5)8.0 (7.0-8.5)6.0 (6.0-7.5)9.0 (5.0-11.5)0.9430.956Hyperemic area11.0 (6.8-12.0)11.5 (7.3-13.4)9.4 (7.5-12.7)13.9 (12.4-4.5)0.4740.500[^3]

Continuous venovenous hemodiafiltration
---------------------------------------

Most patients received CVVHDF via a catheter placed in the right internal jugular vein (88.9%); blood, dialysis and replacement solution flow were kept constant. Median ultrafiltration rate and CVVHDF dose of corresponded to 190mL/hour and 37.1mL/kg/hour, respectively. All patients received citrate anticoagulation during CVVHDF.

Vital signs and NIRS-derived parameters
---------------------------------------

Systemic hemodynamics and peripheral perfusion remained unchanged throughout the experimental period. Heart rate, mean arterial pressure, peripheral hemoglobin saturation as measured by pulse oximetry, forearm-to-fingertip skin temperature gradient and peripheral perfusion index did not change significantly during the first 24 hours of RRT. Minimum SatO~2~ was the only NIRS-derived parameter to differ during the VOT, with a decrease compared to baseline in the first 24 hours after CVVHDF initiation. This association remained significant after adjustment for baseline severity. Also, given hemoglobin levels and temperature may impact minimum SatO~2~ levels, further analysis adjusted for SOFA, SAPS III, baseline hemoglobin levels and temperature measured at different experimental time points was performed. Results of this analysis confirmed previous finding (p=0.017; SatO~2~ variation over time).

DISCUSSION
==========

In this pilot study, CVVHDF had no impact on clinically assessed macrocirculatory or microcirculatory parameters. Minimum SatO~2~ levels measured during VOT was the only NIRS-derived parameter to change (decrease over time) during CVVHDF.

Near-infrared spectroscopy does not allow direct measurement of blood flow and may therefore induce misinterpretation of SatO~2~ values.^(^ [@B9] ^,^ [@B10] ^)^ Analysis of SatO~2~ changes during a brief period of forearm ischemia VOT allows fast, dynamic assessment of the microvascular reserve.^(^ [@B9] ^,^ [@B10] ^)^ Consensus regarding VOT intensity and duration is lacking; however, the VOT used in this study has been well described in literature.^(^ [@B9] ^,^ [@B10] ^)^ Basically, the descending VOT slope is used to estimate thenar muscle oxygen consumption and the ascending slope and hyperemic area to estimate post-ischemic vasodilation and capillary recruitment.^(^ [@B9] ^,^ [@B10] ^)^

Deterioration of the microcirculation during the first 24 hours of CRRT has been reported.^(^ [@B5] ^)^ However, that study was based on a comparatively smaller number of variables. Drop in minimum SatO~2~ values during the experimental period was the only significant change in this study. Minimum SatO~2~ is thought to be an indicator of the extent of ischemia.^(^ [@B11] ^)^ This finding suggests higher oxygen consumption during the first 24 hours of CVVHDF. Also, changes detected in this study may have been caused by CVVHDF, as dialysis may induce pre-capillary sphincter constriction due to changes in electrolyte concentrations and drop in core temperature in response to dialysis against cool dialysate.^(^ [@B5] ^)^

The dissociation between macrocirculation and microcirculation has been described; however, macrocirculation parameters, such as heart rate, mean arterial pressure, cardiac output and central venous oxygen saturation are commonly used to monitor critically ill patients.^(^ [@B10] ^,^ [@B12] ^)^ Also, persistence of microcirculatory abnormalities in spite of macrocirculatory optimization is associated with higher mortality.^(^ [@B4] ^,^ [@B10] ^)^ Hence, microcirculatory monitoring, early optimization of microcirculatory parameters and accurate assessment of intravascular volume for appropriate intervention selection may translate into better outcomes in critically ill patients.^(^ [@B10] ^,^ [@B13] ^,^ [@B14] ^)^

This study has limitations. Being a pilot study with small sample size, it lacks sufficient power to confirm or exclude associations, which can only be suggested. Also, single-center design decreases the external validity of findings, particularly due to use of a specific protocol for CVVHDF in ICU. Moroever, NIRS does not measure microcirculatory flow directly and the NIRS signal is limited to vessels less than 1mm in diameter.^(^ [@B10] ^)^

CONCLUSION
==========

Minimum tissue oxygen saturation measured during the vascular occlusion test was the only near-infrared spectroscopy-derived parameter to change during the first 24 hours of continuous venovenous hemodiafiltration. Further studies with adequate sample size and power are warranted to address the impacts of microcirculatory dysfunction on clinical outcomes of patients undergoing to continuous venovenous hemodiafiltration.

[^1]: **Conflict of interest:** none.

[^2]: Data presented as median (interquartile range) or N/total (%). BMI: body mass index; ICU: intensive care unit; SAPS: Simplified Acute Physiology Score; SOFA: Sequential Organ Failure Assessment; PaO~2~: partial pressure of oxygen; PaCO~2~: partial pressure of carbon dioxide; FiO~2~: inspired oxygen fractions; PBW: predicted body weight; PEEP: positive end-expiratory pressure; CVVHDF: continuous venovenous hemodiafiltration.

[^3]: Data presented as median (interquartile range) or n/total (%). \* p values calculated using linear mixed models; ^†^ adjusted for Simplified Acute Physiology Score III e Sequential Organ Failure Assessment. CVVHDF: continuous venovenous hemodiafiltration; MAP: mean arterial pressure; CVP: central venous pressure; SpO~2~: pulse oximeter saturation; PPI: peripheral perfusion index; RRT: renal replacement therapy; NIRS: near-infrared spectroscopy; THI: tissue hemoglobin index; SatO~2~: tissue oxygen saturation; SatO~2~min: minimum tissue oxygen saturation after arterial occlusion test; StO~2~max: maximum tissue oxygen saturation after arterial occlusion.
